Navigation Links
Escalon(R) Medical Corp. Completes $1.1 Million Private Equity Financing
Date:11/21/2008

laws. Escalon Medical has agreed to file a registration statement covering the resale by the investors of the shares purchased and shares issuable upon exercise of the warrants. This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy shares or warrants and is being issued under Rule 135c under the Securities Act.

Founded in 1987, the Company (http://www.escalonmed.com) develops markets and distributes ophthalmic diagnostic, surgical and pharmaceutical products as well as vascular access devices. Drew Scientific, which operates as a separate business unit, provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases and hematology, as well as veterinary hematology and blood chemistry. The Company seeks to utilize strategic partnerships to help finance its development programs and is also seeking acquisitions to further diversify its product line to achieve critical mass in sales and take better advantage of the Company's distribution capabilities, although such partnerships or acquisitions may not occur. The Company has headquarters in Wayne, Pennsylvania and operations in Long Island, New York, New Berlin, Wisconsin, Lawrence, Massachusetts, Dallas, Texas, Waterbury, Connecticut, Miami, Florida and Barrow-in-Furness, U.K.

Note: This press release contains statements that are considered forward-looking under the Private Securities Litigation Reform Act of 1995, including statements about the Company's future prospects. These statements are based on the Company's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to:

  • implement its growth and marketing strategies
    '/>"/>

SOURCE Escalon Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Escalon(R) Reports First Quarter Fiscal 2009 Results
2. Escalon(R) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer
3. Escalon(R) Enhances Position Within IVD Reagent Market with Strategic Acquisition of JAS Diagnostics
4. Escalon(R) Announces China Registration for Sonomed PacScan(R) and E/Z-Scan(R) Series of A-scan, Pachymeter and B-Scan Systems
5. Escalon(R) Announces Executive Promotions
6. Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System
7. Escalon(R) Reports First Quarter Fiscal 2008 Results
8. Escalon(R) Reports Financial Results for 2007 Fiscal Year
9. OmniVision Unveils 1.8 mm, Low Power Medical Sensor With Best-in-Class Low Light Performance
10. ReachMD Announces New Strategic Partnership with American Medical Directors Association
11. Photos: Nevadas Saint Marys Regional Medical Center Raises $1.3 Million During Centennial Soiree
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Contamination from depleted uranium found in urine 20 years later 2Health News:Red Cross Receives $250,000 From Wal-Mart to Assist With Southern California Wildfire Relief Efforts 2Health News:Red Cross Receives $250,000 From Wal-Mart to Assist With Southern California Wildfire Relief Efforts 3Health News:Marital Stress Linked to Heart Disease 2Health News:Marital Stress Linked to Heart Disease 3Health News:Young Innovations, Inc. Announces Results for the Third Quarter Ended September 30, 2007 and Declares Quarterly Dividend 2Health News:Young Innovations, Inc. Announces Results for the Third Quarter Ended September 30, 2007 and Declares Quarterly Dividend 3Health News:Young Innovations, Inc. Announces Results for the Third Quarter Ended September 30, 2007 and Declares Quarterly Dividend 4Health News:Young Innovations, Inc. Announces Results for the Third Quarter Ended September 30, 2007 and Declares Quarterly Dividend 5Health News:Young Innovations, Inc. Announces Results for the Third Quarter Ended September 30, 2007 and Declares Quarterly Dividend 6Health News:Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality 2Health News:Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality 3Health News:Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality 4
Breaking Medicine Technology:Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 2Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 3Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 4FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Genomes of biofuel yeasts reveal clues that could boost fuel ethanol production worldwide 14759 1Genomes of biofuel yeasts reveal clues that could boost fuel ethanol production worldwide 14759 2Catholics for Choice Statement on Healthcare Reform Bill 60931 1Catholics for Choice Statement on Healthcare Reform Bill 60931 2Findings show nanomedicine promising for treating spinal cord injuries 10653 1Findings show nanomedicine promising for treating spinal cord injuries 10653 2Findings show nanomedicine promising for treating spinal cord injuries 10653 3